Staging Systems for Papillary Thyroid Carcinoma

In Brief Objective: To find out the most applicable and consistent staging system for papillary thyroid carcinoma (PTC) available in the literature. Background: The commonly used staging systems for PTC have predicted cancer-specific survival (CSS) well. However, their applicability and generalizability have not yet been evaluated in different clinical settings. Methods: A MEDLINE search from 1965 to 2005 was carried out to identify different staging systems available in the literature and 9 systems were applicable to 1634 PTC patients within 2 tertiary-referral centers. The CSS of each staging system within individual centers were calculated using Kaplan-Meier method and the CSS of each tumor stage in one individual center was compared with that of the other by log-rank test. In addition, within each center, the predictability of each staging system relative to the others was ranked based on the proportion of variation explained (PVE) value. Results: Clinicopathologic features, treatment received, and tumor stages were significantly different between the 2 centers. There were also significant differences in CSS within at least one tumor stage between the 2 centers in 8 of the 9 staging systems. The TNM was a highly predictive and consistent staging system within the 2 centers. Although the absolute PVE values differed between the 2 centers, the relative ranking of the 9 staging systems within each center correlated significantly to each other (P < 0.05). Conclusions: Despite referral, treatment, and data collection biases inherent within each center, the TNM system remained to be the most applicable and consistent staging system for PTC in 2 centers managing the same population group. Significant differences in clinicopathologic features, treatment modalities received, and tumor stages were found when patients with papillary thyroid carcinoma in 2 tertiary-referral centers were compared. However, despite their differences, the TNM system was the most applicable and consistent staging system for papillary thyroid carcinoma in the 2 centers.